Flow cytometry-based FRET identifies binding intensities in PPARγ1 protein-protein interactions in living cells

Theranostics. 2019 Jul 28;9(19):5444-5463. doi: 10.7150/thno.29367. eCollection 2019.

Abstract

PPARγ is a pharmacological target in inflammatory and metabolic diseases. Upon agonistic treatment or following antagonism, binding of co-factors is altered, which consequently affects PPARγ-dependent transactivation as well as its DNA-independent properties. Therefore, establishing techniques to characterize these interactions is an important issue in living cells. Methods: Using the FRET pair Clover/mRuby2, we set up a flow cytometry-based FRET assay by analyzing PPARγ1 binding to its heterodimerization partner RXRα. Analyses of PPARγ-reporter and co-localization studies by laser-scanning microscopy validated this system. Refining the system, we created a new readout to distinguish strong from weak interactions, focusing on PPARγ-binding to the co-repressor N-CoR2. Results: We observed high FRET in cells expressing Clover-PPARγ1 and mRuby2-RXRα, but no FRET when cells express a mRuby2-RXRα deletion mutant, lacking the PPARγ interaction domain. Focusing on the co-repressor N-CoR2, we identified in HEK293T cells the new splice variant N-CoR2-ΔID1-exon. Overexpressing this isoform tagged with mRuby2, revealed no binding to Clover-PPARγ1, nor in murine J774A.1 macrophages. In HEK293T cells, binding was even lower in comparison to N-CoR2 constructs in which domains established to mediate interaction with PPARγ binding are deleted. These data suggest a possible role of N-CoR2-ΔID1-exon as a dominant negative variant. Because binding to N-CoR2-mRuby2 was not altered following activation or antagonism of Clover-PPARγ1, we determined the effect of pharmacological treatment on FRET intensity. Therefore, we calculated flow cytometry-based FRET efficiencies based on our flow cytometry data. As with PPARγ antagonism, PPARγ agonist treatment did not prevent binding of N-CoR2. Conclusion: Our system allows the close determination of protein-protein interactions with a special focus on binding intensity, allowing this system to characterize the role of protein domains as well as the effect of pharmacological agents on protein-protein interactions.

Keywords: FRET; N-CoR2; NHR co-factors protein-protein interactions; PPARγ1; RXRα; binding affinity and intensity; co-localization analysis; flow cytometry-based FRET assay.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dimerization
  • Flow Cytometry / methods*
  • Fluorescence Resonance Energy Transfer / methods*
  • HEK293 Cells
  • Humans
  • Mice
  • Nuclear Receptor Co-Repressor 1 / chemistry
  • Nuclear Receptor Co-Repressor 1 / genetics
  • Nuclear Receptor Co-Repressor 1 / metabolism
  • PPAR gamma / chemistry
  • PPAR gamma / genetics
  • PPAR gamma / metabolism*
  • Protein Binding
  • Protein Domains
  • Retinoid X Receptor alpha / chemistry
  • Retinoid X Receptor alpha / genetics
  • Retinoid X Receptor alpha / metabolism

Substances

  • NCOR1 protein, human
  • Nuclear Receptor Co-Repressor 1
  • PPAR gamma
  • Retinoid X Receptor alpha